In AD patients, the assessment of clinical signs, Mini Mental State Examination, CSF biomarker (amyloid-β42, total-tau, and phospho-tau) levels, and inflammatory indices (serum c-reactive protein, fibrinogen, D-Dimers) could define the profile of frail AD patients, who are usually non-responders to pharmacological treatment and rapidly progressive [100]. This evidence concerns the gene MAPT and Alzheimer disease.